Management of myelodysplastic syndromes after failure of response to hypomethylating agents
|
May 2019
|
Therapeutic Advances in Hematology
|
myelodysplastic syndromes (MDS)
|
Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes
|
Apr 2019
|
Blood
|
myelodysplastic syndromes (MDS)
|
MDS with 5q deletion and rare cKIT positive mastocytosis: a diagnostic and therapeutic challenge
|
Apr 2019
|
BMJ Case Reports
|
myelodysplastic syndromes (MDS)
|
Use of Immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis
|
Apr 2019
|
Haemotologica
|
myelodysplastic syndromes (MDS)
|
Flaming and fanning: The Spectrum of inflammatory influences in myelodysplastic syndromes
|
Apr 2019
|
Blood Reviews
|
myelodysplastic syndromes (MDS)
|
Eltrombopag for refractory severe aplastic anemia: dosing, duration, long term outcomes and clonal evolution
|
Apr 2019
|
Blood
|
aplastic anemia
|
Getting personal with myelodysplastic syndromes: is now the right time?
|
Apr 2019
|
Expert Review of Hematology
|
myelodysplastic syndromes (MDS)
|
Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study
|
Apr 2019
|
Haematologica
|
aplastic anemia
|
A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS)
|
Mar 2019
|
Leukemia Research
|
myelodysplastic syndromes (MDS)
|
Myelodysplastic Syndromes Treatment (PDQ®): Patient Version
|
Mar 2019
|
National Cancer Institute
|
myelodysplastic syndromes (MDS)
|